Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.

MLA

Sommerer, Claudia, et al. “Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-Month Post Hoc Analysis From TRANSFORM Study.” Transplantation, vol. 107, no. 7, July 2023, pp. 1593–604. EBSCOhost, https://doi.org/10.1097/TP.0000000000004555.

APA

Sommerer, C., Legendre, C., Citterio, F., Watarai, Y., Oberbauer, R., Basic-Jukic, N., Han, J., Gawai, A., Bernhardt, P., & Chadban, S. (2023). Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study. Transplantation, 107(7), 1593–1604. https://doi.org/10.1097/TP.0000000000004555

Chicago

Sommerer, Claudia, Christophe Legendre, Franco Citterio, Yoshihiko Watarai, Rainer Oberbauer, Nikolina Basic-Jukic, Jackie Han, Apurva Gawai, Peter Bernhardt, and Steve Chadban. 2023. “Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-Month Post Hoc Analysis From TRANSFORM Study.” Transplantation 107 (7): 1593–1604. doi:10.1097/TP.0000000000004555.